Follicular lymphoma international prognostic index.

By P. Solal-Céligny, Pascal Roy, Philippe Colombat, Jo M. White, J. Armitage, R. Arranz-Sáez, W. Au, M. Bellei, Pauline Brice, Dolores Caballero and 25 more. Blood, 2004

1,246 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2a7b6852ca1ebc92e4266852925af964b91650a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Webb
2. S. Whittaker
3. T. Mitchell
4. J. Scarisbrick
5. M. Maurer
6. S. Morris
7. E. Wedgeworth
8. M. Cox

Citations in the corpus

• Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (2015, methodology): “Validated tools for risk assessment and prognostication in newly diagnosed FL incorporate clinical and laboratory features applicable to use in the front-line setting.(13,15) Risk stratification at relapse requires more empiricism and is not guided by any particular feature, though, in practice, num”
• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (2006, neutral): “Median platelet count, 109/L (range) 188 (3-1346) 452”
• Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. (2010, result): “prognostic factors in MF/SS remain less well defined compared with other lymphomas.(12,13) Until recently, the MF Cooperative Group of the American Joint Committee on Cancer (AJCC) staging has been used for MF/SS.”